Michiel E. Ultee of Ulteemit BioConsulting discusses converting an early drug discovery into a product that is ready for clinical testing.
In this video, Michiel E. Ultee, PhD, principal of Ulteemit BioConsulting, discusses converting an early drug discovery into a product that is ready for clinical testing, biologics license applications, and FDA guidance documents.
The video was shot at INTERPHEX 2015 in New York, NY.
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.